Unicycive Therapeutics, Inc.
UNCY
$5.12
$0.091.79%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 86.57% | 12.58% | -144.06% | 6.78% | -1,231.05% |
| Total Depreciation and Amortization | -28.44% | 39.74% | 2.03% | 7.25% | 2.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -192.25% | -34.89% | 2,635.61% | -271.07% | 102.53% |
| Change in Net Operating Assets | -211.52% | 139.17% | -969.20% | 110.27% | -26.60% |
| Cash from Operations | -21.84% | 22.30% | -34.72% | 29.19% | 5.43% |
| Capital Expenditure | 112.50% | -- | 100.00% | 66.67% | 62.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.53% | 57.36% | -- | -- | -- |
| Cash from Investing | 99.55% | 57.29% | -603,450.00% | 66.67% | 62.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -26.20% | 196.20% | -74.91% | 139.60% | 306.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 26.12% | -195.12% | 74.85% | -135.55% | -41.80% |
| Cash from Financing | -26.20% | 196.23% | -74.91% | 139.73% | 331.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.63% | 160.55% | -166.27% | 696.25% | 140.14% |